Introduction {#sec1}
============

Furans as oxygen-containing five-membered heterocycles are an important class of biologically active compounds.^[@ref1],[@ref2]^ They are found in nature and in various pharmaceuticals as well as in flavor and fragrance.^[@ref3]^ Synthesis of multisubstituted furans is important not only because of their presence in various biologically active compounds but also because they may serve as key synthetic precursors.^[@ref4]^ Especially, 2-aminomethylfurans are found in many important drugs and natural products ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref2]^ 2-Amino-methylated furans are well accessible from readily available furan building blocks such as furfural via reductive amination reaction, but the synthesis of substituted 2-aminomethylfurans requires multiple steps.^[@cit1a],[@cit2g]−[@cit2i]^

![Drugs and natural products containing the 2-aminomethylfuran motif.](ao-2017-01542a_0001){#fig1}

Owing to their importance, ample examples are reported in the literature detailing the synthesis of substituted furans. Most of the synthetic methods are based on the addition of oxygen to the activated alkene,^[@ref5]^ alkyne,^[@ref6]^ or allene.^[@ref7]^ Opening of the cyclopropane ring and cycloisomerization in inter- or intramolecular fashion are also well-documented in the literature.^[@ref8]^ The majority of synthetic methods require metals as reagents or catalysts such as Ag, Pd, Rh, Cu, Pt, and Fe. A few methods starting from epoxides have also been reported, requiring metallic catalysts including Ag, In, and Pt.^[@ref9]^ However, a metal-free method is highly desired to avoid metal impurities in the synthetic products, especially in biologically relevant compounds.^[@ref10]^ A few methods other than the Paal--Knorr furan synthesis were developed for the synthesis of substituted furans without metal catalysts.^[@cit6c]−[@cit6e],[@ref11]^

Most of them proceeded in an intramolecular fashion with strong acid or iodine as reagents. Some of the reactions required a prerequisite of highly reactive intermediates including silyl enol ether, acid chloride, and so forth.^[@ref12]^ Thereby, a mild and metal-free synthetic method for the preparation of multisubstituted furan is highly desirable for further development of this useful heterocycle.

A few previous synthetic methods with the breakage of highly strained cyclopropane or epoxide have been reported in the literature based on the cycloisomerization.^[@ref8],[@ref9]^ All of these methods proceed by the intermediacy of A, which is more or less similar to the reactive intermediate derived from the acyclic starting material. Oxygen from the carbonyl group of the starting substrate adjacent to cyclopropane or ring-opened epoxide attacks the activated alkynic or allenic appendage with the assistance of metal catalysts such as Cu, Ag, Au, and In.^[@ref5]−[@ref9]^ However, in this study, we developed a completely different method. The suitably disposed carbonyl oxygen ended in the furan ring attacks nonactivated aziridine which is activated by BF~3~·OEt~2~ followed by aromatization to yield furan. This strategy is depicted as B in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. The cyclization with the opening of aziridine for a new heterocyclic compound was observed in our early investigations.^[@ref13]^ However, it has not been shown to make a new ring through the cyclization with the breakage of the aziridine ring in an intramolecular fashion. This extraordinary reaction pathway involving cyclization by heteroatoms at the tether of the starting material with concomitant breakage of the highly strained ring shows a possibility to develop new methods for the preparation of various heterocycles.

![Highly substituted furan (**1**) and its general synthetic method involving metal-mediated cyclization (A) compared to the method (B) derived from the breakage of an aziridine ring.](ao-2017-01542a_0002){#fig2}

The key for the success is the breaking of the aziridine ring by the nearby oxygen. Normally, most of the "activated" aziridines readily react with the incoming nucleophile at the less hindered site without any controllable regiochemical diversity.^[@ref14]^ Another chemical method to make ring opening easy is to design the starting substrate with olefin for allylic activation.^[@ref15]^ Even though we have studied aziridine for quite a long time,^[@ref13]^ we were not able to open the "unactivated" aziridine rings with the internal oxygen so far because of the intrinsic inertness of the ring opening. Aziridine in this synthesis is "unactivated" with the electron-donating substituent at the ring nitrogen and is quite stable and inert to almost all nucleophiles.^[@ref15],[@ref16]^ These "unactivated" aziridines should be activated before they react with nucleophiles.^[@ref17]^ However, they have a big advantage on the regiochemical diversity, that is, their ring can be opened either at C2 or at C3 and is completely controllable by the selection of activators and nucleophiles.^[@ref15]−[@ref17]^

Results and Discussion {#sec2}
======================

At first, we prepared diethyl 2-(aziridin-2-ylmethylene)malonate (**2a**) having suitably disposed carbonyl oxygen located near aziridine being ready to attack for the ring opening. Initially, aziridinyl malonate (**2a**) was treated with 1.05 equiv of BF~3~·OEt~2~ and sodium acetate in CH~2~Cl~2~ at room temperature (rt) for 4 h to expect the usual intermolecular aziridine ring-opening product **3a′**. Much to our surprise, only intramolecular aziridine ring-opening product **3a** was formed in 85% yields without furnishing any traces of the product arising from the intermolecular ring opening ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Synthesis of Multisubstituted Furan **3a** from Diethyl 2-\[((*R*)-(1-(*R*)-(1-Phenylethyl)aziridin-2-yl)methylene)\]malonate (**2a**)](ao-2017-01542a_0003){#sch1}

Once the structure of furan **3a** was confirmed, the same reaction was performed without using external nucleophile sodium acetate and the same results were observed as above. To improve the reaction yield for the conversion of aziridines to furan derivatives, various Lewis acids such as AlCl~3~, CeCl~3~, I~2~, and/or FeCl~3~ were screened ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Among them, only BF~3~·OEt~2~ and FeCl~3~ yielded the expected product, and BF~3~·OEt~2~ was the most effective.

###### Formation of Multisubstituted Furans (**3a**) from 2-(Aziridin-2-ylmethylene)malonate (**2a**) with Various Lewis Acids

![](ao-2017-01542a_0007){#GRAPHIC-d213e380-autogenerated}

  entry   Lewis acid (1.05 equiv)   time (h)   yield (%)
  ------- ------------------------- ---------- -----------
  1       BF~3~·OEt~2~              3.0        85
  2       AlCl~3~                   12.0       0
  3       CeCl~3~                   4.0        0
  4       I~2~                      12         0
  5       FeCl~3~                   4.5        36

Several different aziridines were utilized for the intramolecular ring-opening reaction, leading to the synthesis of various aminomethylfurans in good to moderate yields ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}).

###### Synthesis of Multisubstituted Furans (**3**) from 2-(Aziridin-2-ylmethylene)malonate or 1,3-Dione (**2**) with BF~3~·OEt~2~[a](#t2fn1){ref-type="table-fn"}

![](ao-2017-01542a_0008){#gr7}

Reaction conditions: 1,3-dione **2** (1.0 equiv) and BF~3~·OEt~2~ (1.05 equiv) in CH~2~Cl~2~ (0.3 M) at rt.

Starting ketone **2p** was prepared in situ and directly converted to furan derivative **3p**.

The optimized reaction protocol was applied for the starting materials with various substituents, that is, R^1^ at the nitrogen of 2-(aziridin-2-ylmethylene)malonate and/or 1,3-dione including 2-phenylethyl (**2a**, **2b**, **2c**, **2l**, **2m**, **2n**, **2o**, and **2p**), benzyl (**2d** and **2e**), *t*-butyl (**2f**, **2g**, and **2h**), *c*-hexyl (**2i** and **2j**), and *n*-hexyl (**2k**) groups without altering the reaction yields. No difference was observed in the reaction yields by changing the alkyl esters (R^3^ and/or R^4^) of 2-(aziridin-2-ylmethylene)malonate, whether they are methyl (**2b** and **2f**), ethyl (**2a**, **2d**, **2g**, **2i**, **2l**, and **2m**), or *i*-Pr (**2c**, **2e**, **2h**, **2j**, and **2k**). The same starting malonates decorated with the additional methyl (**2l**, R^2^ = Me) and *i*-Pr (**2m**, R^2^ = *i*-Pr) groups at the β-position aiming for the substituent at C4 of the furan ring yielded the expected products (**3l** and **3m**) with the same efficiency. Under the same reaction conditions, the starting substrate (**2n**) bearing ester (R^4^ = OEt) and ketone (R^3^ = Me) at each side (*E*-/*Z*-mixture) also afforded the product (**3n**) in 80% yield. The product **3n** retaining the methylcarbonyl group at the C3 position of furan suggested us that the aziridine ring opening proceeded by more electron-rich ester oxygen instead of the ketone oxygen. A striking feature of this reaction was represented by the reactions with ketones, as shown in **2o** (R^3^ and R^4^ = Me) and **2p** (R^3^ and R^4^ = −CH~2~CH~2~CH~2~−) to produce furans **3o** and **3p** in 85 and 77% yields, respectively. The formation of these products is ascribed to the breakage of the aziridine ring by ketone oxygen. All of the reactions afforded the expected products in \>75% yield with complete conservation of the starting atoms to the products, that is, with high degree of atom economy ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}).

A plausible mechanism of this reaction is detailed in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. Lewis acid activates the aziridine ring (**I**) of the starting material **2** by coordinating with the lone pair electrons in the ring nitrogen which was observed in our earlier study.^[@ref18]^ At this stage, the ring is highly activated toward the incoming nucleophile, that is, the suitably disposed carbonyl oxygen with the breakage of the carbon--nitrogen bond in aziridine as in **I** to yield **II**. This dominant regioselectivity is directed by the allylic activation and by the preference of 5-*exo*-tet cyclization according to Baldwin's rule.^[@ref15],[@ref16],[@ref19]^ Then, the aromatization via deprotonation of the acidic proton next to the aminomethyl substituent as in **II** afforded furan **3**.

![Mechanism of the Formation of Furan **3a** and γ-Lactone **5** from Unsaturated Ester **2a** and Saturated Ester **4**, Respectively](ao-2017-01542a_0004){#sch2}

A corroborating evidence of this mechanism was found from the same reaction with the saturated substrate, diethyl 2-(aziridin-2-ylmethyl)malonate **4**, affording γ-lactone **5** instead of furan ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). When the proton at C2 of aziridine is not acidic enough, dealkylation to form γ-lactone **5** is more dominant rather than aromatization. Therefore, furan **3** and lactone **5** from dialkyl 2-(aziridin-2-ylmethylene)malonate **2a** and dialkyl 2-(aziridin-2-ylmethyl)malonate **4** were obtained from the similar intermediate **I** in the presence of Lewis acid BF~3~OEt~2~, respectively. This reaction proceeded without any metallic additives as catalysts or reagents with complete conservation of all of the starting atoms to the products, that is, as a high degree of atom-economical synthesis.

Taking advantage of this synthetic method to get highly substituted furan especially with aminomethyl appendage at C5, we treated aminomethylfuran **3b** with 1.0 equiv of dimethyl acetylenedicarboxylate (DMAD) and obtained Michael addition product **6** in quantitative yields. The reaction of aminomethylfuran **3b** with 2.0 equiv of DMAD afforded highly functionalized polycyclic compound **7** as a single isomer, confirmed by the NMR spectra ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

![Conversion of Furan **3b** to Michael Adduct **6** and Polycyclic Compound **7**](ao-2017-01542a_0005){#sch3}

The crystalline structure of the single stereoisomeric product **7** confirmed four new stereocenters generated from the stereoselective conjugate addition^[@ref20]^ and cycloaddition reactions.^[@ref21]^ Furthermore, it should be noted that all of the atoms in one furan and two acetylenedicarboxylates are completely retained in the adduct without the loss of any atom. On the basis of the above observation, the plausible reaction mechanism for the formation of compound **7** from aminomethylfuran **3b** via Michael adduct **6** is proposed ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}).

![Plausible Reaction Mechanism for the Formation of Compound **7**](ao-2017-01542a_0006){#sch4}

Conclusions {#sec3}
===========

In conclusion, we developed a new synthetic method for highly substituted furans from 2-(aziridin-2-ylmethylene)malonate and/or 1,3-dione via aziridine ring opening by the internal carbonyl oxygen with the assistance of BF~3~·OEt~2~ followed by aromatization. This synthetic method is free from any metal and is highly atom-economical with all of the atoms in the starting material retained in the final product.

Experimental Section {#sec4}
====================

General Information {#sec4-1}
-------------------

Chiral aziridines are available from Sigma-Aldrich as reagents and from Imagene Co., Ltd. (<http://www.imagene.co.kr/>) in bulk quantities. All commercially available compounds were used as received unless stated otherwise. All reactions were carried out under a nitrogen atmosphere in oven-dried glassware with a magnetic stirrer. Dichloromethane was distilled from calcium hydride. Reactions were monitored by thin-layer chromatography (TLC) with 0.25 mm E Merck precoated silica gel plates (60 F254). Visualization was accomplished either with UV light or by immersion in solutions of ninhydrin, *p*-anisaldehyde, or phosphomolybdic acid, followed by heating on a hot plate for about 10 s. Purification of reaction products was carried out by flash chromatography using Kieselgel 60 Art 9385 (230--400 mesh). ^1^H NMR and ^13^C NMR spectra were obtained using a Varian unity lNOVA 400 WB (400 MHz) or Bruker AVANCE III HD (400 MHz) spectrometer. Chemical shifts are reported relative to chloroform (δ = 7.26) for ^1^H NMR and chloroform (δ = 77.2) for ^13^C NMR and acetonitrile (δ = 1.94) for ^1^H NMR and acetonitrile (δ = 1.32) for ^13^C NMR. Data are reported as (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, p = quintet, and m = multiplet). Coupling constants are given in hertz. Ambiguous assignments were resolved based on standard one-dimensional proton decoupling experiments. Optical rotations were obtained using a RUDOLPH AUTOPOL III digital polarimeter and a JASCO P-2000 polarimeter. Optical rotation data were reported as follows: \[α\]^20^ (concentration *c* = g/100 mL, solvent). High-resolution mass spectra were recorded on a 4.7 Tesla IonSpec ESI-TOFMS instrument, and JEOL (JMS-700) and AB SCIEX 4800 Plus MALDI TOF (2,5-dihydroxybenzoic acid) matrix were used to prepare samples for mass spectrometry. Data were obtained in the reflector positive mode with internal standards for calibration.

General Procedure for the Synthesis of Multisubstituted Furan (**3**) {#sec4-2}
---------------------------------------------------------------------

To a stirred solution of dialkyl 2-(aziridin-2-ylmethylene)malonate or 2-(aziridin-2-ylmethylene)-1,3-dione **2** (500 mg, 1.57 mmol) in CH~2~Cl~2~ (5.0 mL) was added BF~3~·OEt~2~ (0.20 mL, 1.65 mmol) at ambient temperature. The reaction mixture was allowed to stir for 4 h ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). After completion of the reaction as confirmed by TLC (50% EtOAc/hexane), the mixture was quenched with aq NaHCO~3~ (5.0 mL) and extracted with CH~2~Cl~2~ (10 × 3 mL). The combined organic layer was dried over anhydrous Na~2~SO~4~, and the solvent was removed in vacuo. This crude product was purified by column chromatography to provide analytically pure furan **3**.

### (*R*)-Ethyl 2-Ethoxy-5-\[(1-phenylethylamino)methyl\]furan-3-carboxylate (**3a**) {#sec4-2-1}

\[α\]~D~^20^ = +71.8 (*c* = 0.98, CHCl~3~); *R*~f~ = 0.48 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.39--7.21 (m, 5H), 6.32 (s, 1H), 4.43 (q, *J* = 7.1 Hz, 2H), 4.25 (q, *J* = 7.1 Hz, 2H), 3.80 (q, *J* = 6.6 Hz, 1H), 3.50 (ABq, *J* = 14.8 Hz, 2H), 1.75 (br s, 1H), 1.45 (t, *J* = 7.1 Hz, 3H), 1.36 (d, *J* = 6.6 Hz, 3H), 1.32 (t, *J* = 7.1 Hz, 3H); ^13^C NMR (CDCl~3~, 101 MHz): δ 163.0, 161.2, 144.7, 143.4, 128.3, 126.9, 126.5, 108.2, 92.6, 67.9, 59.6, 56.6, 43.4, 24.1, 14.8, 14.2; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~18~H~23~NO~4~Na, 340.1520; found, 340.1537.

### (*R*)-Methyl 2-Methoxy-5-\[(1-phenylethylamino)methyl\]-furan-3-carboxylate (**3b**) {#sec4-2-2}

\[α\]~D~^20^ = +57.0 (*c* = 1.08, CHCl~3~); *R*~f~ = 0.40 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.36--7.27 (m, 4H), 7.26--7.19 (m, 1H), 6.32 (s, 1H), 4.05 (s, 3H), 3.83--3.70 (m, 4H), 3.47 (ABq, *J* = 14.9 Hz, 2H), 1.70 (br s, 1H), 1.34 (d, *J* = 6.7 Hz, 3H); ^13^C NMR (CDCl~3~, 101 MHz): δ 162.9, 161.1, 144.5, 143.3, 128.0, 126.6, 126.2, 108.1, 91.0, 57.6, 56.4, 50.6, 43.1, 23.9; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~16~H~19~NO~4~Na, 312.1207; found, 312.1203.

### (*R*)-Isopropyl 2-Isopropoxy-5-\[(1-phenylethylamino)-methyl\]-furan-3-carboxylate (**3c**) {#sec4-2-3}

\[α\]~D~^20^ = +57.7 (*c* = 1.65, CHCl~3~); *R*~f~ = 0.55 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.36--7.29 (m, 4H), 7.27--7.22 (m, 1H), 6.30 (s, 1H), 5.18--5.07 (m, 1H), 4.93--4.83 (m, 1H), 3.79 (q, *J* = 6.6 Hz, 1H), 3.50 (ABq, *J* = 14.8 Hz, 2H), 1.73 (br s, 1H), 1.40 (d, *J* = 6.2 Hz, 6H), 1.35 (d, *J* = 6.6 Hz, 3H), 1.29 (d, *J* = 6.3 Hz, 6H); ^13^C NMR (CDCl~3~, 101 MHz): δ 162.7, 160.8, 144.8, 143.8, 128.4, 127.0, 126.6, 108.1, 95.1, 77.0, 66.9, 56.6, 43.6, 24.1, 22.3, 22.0; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~20~H~27~NO~4~Na, 368.1833; found, 368.1820.

### Ethyl 5-\[(Benzylamino)methyl\]-2-ethoxyfuran-3-carboxylate (**3d**) {#sec4-2-4}

*R*~f~ = 0.40 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.34--7.30 (m, 4H), 7.27--7.22 (m, 1H), 6.39 (s, 1H), 4.43 (q, *J* = 7.1 Hz, 2H), 4.25 (q, *J* = 7.1 Hz, 2H), 3.78 (s, 2H), 3.66 (d, *J* = 0.7 Hz, 2H), 1.73 (br s, 1H), 1.44 (t, *J* = 7.1 Hz, 3H), 1.32 (t, *J* = 7.1 Hz, 3H); ^13^C NMR (CDCl~3~, 101 MHz): δ 163.0, 161.3, 143.2, 139.6, 128.3, 128.1, 127.0, 108.6, 92.7, 68.0, 59.7, 52.4, 45.0, 14.9, 14.3; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~17~H~21~NO~4~Na, 326.1363; found, 326.1352.

### Isopropyl 5-\[(Benzylamino)methyl\]-2-isopropoxyfuran-3-carboxylate (**3e**) {#sec4-2-5}

*R*~f~ = 0.60 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.35--7.27 (m, 4H), 7.26--7.20 (m, 1H), 6.39 (s, 1H), 5.18--5.08 (m, 1H), 4.94--4.84 (m, 1H), 3.76 (s, 2H), 3.64 (s, 2H), 1.77 (br s, 1H), 1.40 (d, *J* = 6.2 Hz, 6H), 1.29 (d, *J* = 6.3 Hz, 6H); ^13^C NMR (CDCl~3~, 101 MHz): δ 162.4, 160.6, 143.4, 139.5, 128.1, 127.9, 126.7, 108.1, 94.9, 76.8, 66.6, 52.2, 44.8, 22.1, 21.7; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~19~H~25~NO~4~Na, 354.1676; found, 354.1660.

### Methyl 5-\[(*tert*-Butylamino)methyl\]-2-methoxyfuran-3-carboxylate (**3f**) {#sec4-2-6}

*R*~f~ = 0.50 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 6.38 (s, 1H), 4.10 (s, 3H), 3.80 (s, 3H), 3.64 (d, *J* = 0.7 Hz, 2H), 1.60 (br s, 1H), 1.15 (s, 9H); ^13^C NMR (CDCl~3~, 101 MHz): δ 163.4, 161.4, 144.3, 107.9, 91.6, 58.1, 51.1, 50.6, 39.6, 28.8; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~12~H~19~NO~4~Na, 264.1207; found, 264.1214.

### Ethyl 5-\[(*tert*-Butylamino)methyl\]-2-ethoxyfuran-3-carboxylate (**3g**) {#sec4-2-7}

*R*~f~ = 0.40 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 6.39 (s, 1H), 4.44 (q, *J* = 7.1 Hz, 2H), 4.25 (q, *J* = 7.1 Hz, 2H), 3.64 (d, *J* = 0.7 Hz, 2H), 1.76 (br s, 1H), 1.45 (t, *J* = 7.1 Hz, 3H), 1.32 (t, *J* = 7.1 Hz, 3H), 1.16 (s, 9H); ^13^C NMR (CDCl~3~, 101 MHz): δ 163.1, 161.3, 144.1, 107.7, 93.0, 68.2, 59.7, 50.7, 39.7, 28.8, 14.9, 14.3; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~14~H~23~NO~4~Na, 292.1520; found, 292.1534.

### Isopropyl 5-\[(*tert*-Butylamino)methyl\]-2-isopropoxyfuran-3-carboxylate (**3h**) {#sec4-2-8}

*R*~f~ = 0.50 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 6.37 (s, 1H), 5.18--5.07 (m, 1H), 4.96--4.85 (m, 1H), 3.64 (d, *J* = 0.6 Hz, 2H), 1.77 (br s, 1H), 1.40 (d, *J* = 6.2 Hz, 6H), 1.29 (d, *J* = 6.3 Hz, 6H), 1.15 (s, 9H); ^13^C NMR (CDCl~3~, 101 MHz): δ 162.7, 160.7, 144.5, 107.4, 95.3, 77.1, 66.9, 50.6, 39.7, 28.8, 22.3, 21.9; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~16~H~27~NO~4~Na, 320.1833; found, 320.1848.

### Ethyl 5-\[(Cyclohexylamino)methyl\]-2-ethoxyfuran-3-carboxylate (**3i**) {#sec4-2-9}

*R*~f~ = 0.40 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 6.38 (s, 1H), 4.43 (q, *J* = 7.1 Hz, 2H), 4.25 (q, *J* = 7.1 Hz, 2H), 3.69 (s, 2H), 2.51--2.40 (m, 1H), 1.91--1.83 (m, 2H), 1.79 (br s, 1H), 1.77--1.70 (m, 2H), 1.65--1.57 (m, 1H), 1.44 (t, *J* = 7.1 Hz, 3H), 1.32 (t, *J* = 7.1 Hz, 3H), 1.27--1.16 (m, 3H), 1.15--1.04 (m, 2H); ^13^C NMR (CDCl~3~, 101 MHz): δ 163.1, 161.3, 143.5, 108.3, 92.8, 68.0, 59.8, 55.3, 42.8, 33.1, 26.0, 24.8, 14.9, 14.3; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~16~H~25~NO~4~Na, 318.1676; found, 318.1677.

### Isopropyl 5-\[(Cyclohexylamino)methyl\]-2-isopropoxyfuran-3-carboxylate (**3j**) {#sec4-2-10}

*R*~f~ = 0.60 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 6.35 (s, 1H), 5.17--5.07 (m, 1H), 4.89 (sep, *J* = 6.2 Hz, 1H), 3.68 (d, *J* = 0.6 Hz, 2H), 2.44 (tt, *J* = 10.3, 3.8 Hz, 1H), 1.89--1.81 (m, 2H), 1.77 (br s, 1H), 1.75--1.68 (m, 2H), 1.65--1.57 (m, 1H), 1.40 (d, *J* = 6.2 Hz, 6H), 1.29 (d, *J* = 6.3 Hz, 6H), 1.27--1.16 (m, 3H), 1.15--1.03 (m, 2H); ^13^C NMR (CDCl~3~, 101 MHz): δ 162.7, 160.7, 144.1, 107.9, 95.1, 77.0, 66.9, 55.1, 42.8, 33.1, 25.9, 24.8, 22.3, 21.9; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~18~H~29~NO~4~Na, 346.1990; found, 346.2002.

### Isopropyl 5-\[(Hexylamino)methyl\]-2-isopropoxyfuran-3-carboxylate (**3k**) {#sec4-2-11}

*R*~f~ = 0.60 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 6.40 (s, 1H), 5.17--5.07 (m, 1H), 4.96--4.86 (m, 1H), 3.68 (s, 2H), 2.60 (t, *J* = 7.3 Hz, 2H), 2.12 (br s, 1H), 1.55--1.46 (m, 2H), 1.40 (d, *J* = 6.2 Hz, 6H), 1.33--1.24 (m, 12H), 0.88 (t, *J* = 6.8 Hz, 3H); ^13^C NMR (CDCl~3~, 101 MHz): δ 162.7, 160.9, 108.7, 95.1, 77.1, 67.0, 48.5, 45.6, 31.6, 29.6, 29.5, 26.9, 22.5, 22.3, 22.0, 13.9; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~18~H~31~NO~4~Na, 348.2146; found, 348.2153.

### (*R*)-Ethyl 2-Ethoxy-4-methyl-5-\[(1-phenylethylamino)-methyl\]furan-3-carboxylate (**3l**) {#sec4-2-12}

\[α\]~D~^20^ = +44.0 (*c* = 1.14, CHCl~3~); *R*~f~ = 0.50 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.38--7.29 (m, 4H), 7.27--7.22 (m, 1H), 4.39 (q, *J* = 7.1 Hz, 2H), 4.25 (q, *J* = 7.1 Hz, 2H), 3.75 (q, *J* = 6.6 Hz, 1H), 3.50 (ABq, *J* = 14.7 Hz, 2H), 2.36 (br s, 1H), 1.95 (s, 3H), 1.43 (t, *J* = 7.1 Hz, 3H), 1.37--1.29 (m, 6H); ^13^C NMR (CDCl~3~, 101 MHz): δ 163.8, 161.6, 144.7, 139.1, 128.4, 127.0, 126.6, 118.1, 92.7, 67.4, 59.4, 56.6, 40.8, 24.2, 14.9, 14.3, 10.0; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~19~H~25~NO~4~Na, 354.1676; found, 354.1669.

### (*R*)-Ethyl 2-Ethoxy-4-isopropyl-5-\[(1-phenylethylamino)-methyl\]furan-3-carboxylate (**3m**) {#sec4-2-13}

\[α\]~D~^20^ = +18.5 (*c* = 0.97, CHCl~3~); *R*~f~ = 0.55 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.37--7.30 (m, 4H), 7.28--7.22 (m, 1H), 4.36 (q, *J* = 7.1 Hz, 2H), 4.25 (q, *J* = 7.1 Hz, 2H), 3.77 (q, *J* = 6.6 Hz, 1H), 3.55 (ABq, *J* = 14.6 Hz, 2H), 3.15--3.04 (m, 1H), 1.87 (br s, 1H), 1.42 (t, *J* = 7.1 Hz, 3H), 1.36--1.30 (m, 6H), 1.22--1.17 (m, 6H); ^13^C NMR (CDCl~3~, 101 MHz): δ 163.7, 161.7, 145.0, 138.9, 128.4, 128.0, 127.0, 126.6, 92.0, 67.3, 59.5, 56.9, 42.3, 24.8, 24.3, 22.1, 14.9, 14.3; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~21~H~29~NO~4~Na, 382.1990; found, 382.2005.

### (*R*)-1-(2-Ethoxy-5-\[(1-phenylethylamino)methyl\]furan-3-yl)ethanone (**3n**) {#sec4-2-14}

\[α\]~D~^20^ = +69.0 (*c* = 1.07, CHCl~3~); *R*~f~ = 0.40 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.38--7.29 (m, 4H), 7.28--7.21 (m, 1H), 6.38 (s, *J* = 3.9 Hz, 1H), 4.48--4.41 (m, 2H), 3.79 (q, *J* = 6.6 Hz, 1H), 3.50 (ABq, *J* = 14.9 Hz, 2H), 2.36 (s, 3H), 1.79 (br s, 1H), 1.46 (t, *J* = 7.1 Hz, 3H), 1.35 (d, *J* = 6.6 Hz, 3H); ^13^C NMR (CDCl~3~, 101 MHz): δ 191.4, 161.3, 144.7, 144.1, 128.3, 126.9, 126.5, 107.2, 102.4, 67.3, 56.6, 43.4, 28.3, 24.1, 14.8; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~17~H~21~NO~3~Na, 310.1414; found, 310.1413.

### (*R*)-1-(2-Methyl-5-\[(1-phenylethylamino)methyl\]furan-3-yl\]ethanone (**3o**) {#sec4-2-15}

\[α\]~D~^20^ = +53.3 (*c* = 4.12, CHCl~3~); *R*~f~ = 0.45 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.39--7.16 (m, 5H), 6.31 (s, 1H), 3.79 (q, *J* = 6.6 Hz, 1H), 3.56 (ABq, *J* = 14.6 Hz, 2H), 2.54 (s, 3H), 2.34 (s, 3H), 1.74 (br s, 1H), 1.36 (d, *J* = 6.6 Hz, 3H); ^13^C NMR (CDCl~3~, 101 MHz): δ 193.7, 157.3, 151.6, 144.5, 128.2, 126.7, 126.3, 121.5, 107.1, 56.9, 43.4, 28.7, 24.0, 14.0; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~16~H~19~NO~2~Na, 280.1308; found, 280.1300.

### (*R*)-2-\[(1-Phenylethylamino)methyl\]-6,7-dihydrobenzofuran-4(5*H*)-one (**3p**) {#sec4-2-16}

Piperidine (10 μL, 0.1 mmol) was added to a stirred solution of aziridinyl aldehyde (175 mg, 1.0 mmol), cyclohexane-1,3-dione (118 mg, 1.05 mmol), and 4 Å molecular sieves (dry powder, 0.2 g) in CH~2~Cl~2~ (4.0 mL) at rt, and the reaction mixture was allowed to stir for 12 h. BF~3~·OEt~2~ (0.16 mL, 1.3 mmol) was added to the reaction mixture and stirred for 6.0 h. The reaction mixture was filtered through Celite and washed with CH~2~Cl~2~ (3 × 15 mL). The combined organic layer was washed with aq NaHCO~3~ (5.0 mL), and the solvents were removed under vacuum to get a crude product, which was purified by column chromatography on silica gel to get pure product **3p** (207 mg, 77%). \[α\]~D~^20^ = +73.6 (*c* = 1.02, CHCl~3~); *R*~f~ = 0.40 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.36--7.18 (m, 5H), 6.35 (s, 1H), 3.78 (q, *J* = 6.6 Hz, 1H), 3.58 (ABq, *J* = 14.7 Hz, 2H), 2.80 (t, *J* = 6.3 Hz, 2H), 2.46--2.38 (m, 2H), 2.15--2.04 (m, 2H), 1.82 (br s, 1H), 1.34 (d, *J* = 6.7 Hz, 3H); ^13^C NMR (CDCl~3~, 101 MHz): δ 193.7, 166.1, 153.9, 144.3, 128.0, 126.5, 126.2, 121.2, 102.9, 56.5, 43.2, 37.0, 23.8, 22.8, 22.1; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~17~H~19~NO~2~Na, 270.1489; found, 270.1477.

### (*R*)-Ethyl 2-Oxo-5-\[(1-phenylethylamino)methyl\]tetrahydro-furan-3-carboxylate (**5**) {#sec4-2-17}

#### Procedure A {#sec4-2-17-1}

BF~3~·OEt~2~ (0.16 mL, 1.3 mmol) was added to a solution of ester **4** (160 mg, 0.5 mmol) in CH~2~Cl~2~ (4.0 mL), and the mixture was stirred for 24 h at rt. The reaction mixture was quenched with aq NaHCO~3~ and extracted with CH~2~Cl~2~, and the combined organic layer was dried over Na~2~SO~4~. The solvents were removed under vacuum to get a crude product, which was purified by column chromatography to yield pure lactone **5** (81 mg, 56%).

#### Procedure B {#sec4-2-17-2}

BF~3~·OEt~2~ (0.16 mL, 1.3 mmol) was added to a solution of ester **4** (160 mg, 0.5 mmol) in acetonitrile (4.0 mL), and the mixture was refluxed for 2.0 h at 90 °C. The reaction mixture was cooled to rt and quenched with aq NaHCO~3~. The reaction mixture was extracted with CH~2~Cl~2~ (3 × 10 mL), the combined organic layer was dried over Na~2~SO~4~, and the solvents were removed under vacuum to get a crude product, which was purified by column chromatography to yield pure lactone **5** (125 mg, 86%). *R*~f~ = 0.30 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CD~3~CN): δ 7.37--7.30 (m, 4H), 7.27--7.20 (m, 1H), 4.68--4.59 (m, 0.5H), 4.55--4.46 (m, 0.5H), 4.24--4.13 (m, 2H), 3.76 (dq, *J* = 10.2, 6.6 Hz, 1H), 3.67 (dt, *J* = 10.6, 8.1 Hz, 1H), 2.81--2.71 (m, 1H), 2.61--2.21 (m, 3H), 2.12 (br s, 1H), 1.33--1.21 (m, 6H); HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~16~H~21~NO~4~Na, 314.1363; found, 314.1373.

### (*R*)-Dimethyl 2-\[((5-Methoxy-4-(methoxycarbonyl)furan-2-yl)methyl)(1-phenylethyl)amino\]-maleate (**6**) {#sec4-2-18}

A mixture of aminomethylfuran **3b** (200 mg, 0.69 mmol) and DMAD (84 μL, 0.69 mmol) in a sealed tube was stirred for 1 h at 90 °C. The reaction mixture was purified by column chromatography to get pure compound **6** (288 mg, 97% yield). \[α\]~D~^20^ = +66.7 (*c* = 1.0, CHCl~3~); *R*~f~ = 0.40 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.45--7.25 (m, 5H), 6.25 (s, 1H), 4.86 (s, 1H), 4.78 (q, *J* = 6.8 Hz, 1H), 4.02 (s, 3H), 3.96 (s, 3H), 3.92 (s, 2H), 3.76 (s, 3H), 3.64 (s, 3H), 1.64 (d, *J* = 6.9 Hz, 3H); ^13^C NMR (CDCl~3~, 101 MHz): δ 167.8, 166.0, 163.0, 161.0, 153.7, 138.7, 138.6, 128.6, 128.0, 127.3, 110.2, 91.5, 86.4, 58.7, 57.9, 53.0, 51.1, 50.8, 41.5, 17.0; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~22~H~25~NO~8~Na, 454.1473; found, 454.1460.

### (4*aS*,5*R*,6*S*,8*aR*)-Pentamethyl 6-Methoxy-2-((*R*)-1-phenylethyl)-2,4*a*,5,6-tetrahydro-1*H*-6,8*a*-epoxyisoquinoline-3,4,5,7,8-pentacarboxylate (**7**) {#sec4-2-19}

A mixture of aminomethylfuran **3b** (200 mg, 0.69 mmol) and DMAD (0.17 mL, 1.4 mmol) in a sealed tube was stirred for 12 h at 90 °C. The reaction mixture was purified by column chromatography to get pure compound **7** (285 mg, 72% yield). \[α\]~D~^20^ = +1.6 (*c* = 0.62, CHCl~3~); *R*~f~ = 0.35 (EtOAc/hexane, 50%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.43--7.28 (m, 5H), 4.68 (q, *J* = 6.8 Hz, 1H), 3.94 (s, 3H), 3.79 (s, 3H), 3.73 (s, 3H), 3.72 (s, 3H), 3.59 (s, 3H), 3.54 (s, 3H), 3.25 (ABq, *J* = 14.4 Hz, 2H), 3.11 (d, *J* = 4.2 Hz, 1H), 3.03 (d, *J* = 4.2 Hz, 1H), 1.56 (d, *J* = 6.8 Hz, 3H); ^13^C NMR (CDCl~3~, 101 MHz): δ 170.6, 167.1, 166.2, 162.3, 162.0, 148.1, 145.5, 141.0, 138.4, 128.7, 128.0, 127.5, 112.6, 96.7, 80.1, 58.2, 57.3, 54.8, 53.0, 52.6, 52.4, 52.2, 51.0, 44.4, 41.5, 17.3; HRMS-MALDI (*m*/*z*): \[M + Na\]^+^ calcd for C~28~H~31~NO~12~Na, 574.1920; found, 574.1913.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.7b01542](http://pubs.acs.org/doi/abs/10.1021/acsomega.7b01542).General experimental procedures for starting materials (**2a--2o**), ^1^H and ^13^C NMR spectra of all prepared compounds, and X-ray crystallographic data for compound **7** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01542/suppl_file/ao7b01542_si_001.pdf))
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